

Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Dihydrostreptomycin Sulfate Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

20 Spartan Road

1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2 H319: Causes serious eye irritation.

Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.

H372 Causes damage to organs through prolonged or re-

peated exposure.



Dihydrostreptomycin Sulfate Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 5918691-00010 Date of first issue: 20.05.2020

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear eye protection/ face protection.

Response:

P314 Get medical advice/ attention if you feel unwell. P337 + P313 If eye irritation persists: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Dihydrostreptomycin sulphate

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
	Index-No.		
	Registration number		
Dihydrostreptomycin sulphate	5490-27-7	STOT RE 1; H372	>= 30 - < 50
	226-823-7	(ear, Kidney, inner	
		ear)	
Sodium metabisulphite	7681-57-4	Acute Tox. 4; H302	>= 1 - < 3
	231-673-0	Eye Dam. 1; H318	
	016-063-00-2		

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.



Dihydrostreptomycin Sulfate Formulation

VersionRevision Date:SDS Number:Date of last issue: 04.04.20232.130.09.20235918691-00010Date of first issue: 20.05.2020

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes serious eye irritation.

Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Sulphur oxides Metal oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.



Dihydrostreptomycin Sulfate Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 5918691-00010 Date of first issue: 20.05.2020

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Do not breathe decomposition products.



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Dihydrostreptomy- cin sulphate	5490-27-7	TWA	0.4 mg/m3 (OEB 2)	
	Further information: OTO			
		Wipe limit	Not required	
Sodium metabisul- phite	7681-57-4	OEL-RL	10 mg/m3	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			

Occupational exposure limits of decomposition products

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sulphur dioxide	7446-09-5	OEL- RL STEL/C	0,5 ppm	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
		TWA	0,5 ppm 1,3 mg/m3	2017/164/EU
		STEL	1 ppm 2,7 mg/m3	2017/164/EU



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium metabisul- phite	Workers	Inhalation	Long-term systemic effects	225 mg/m3
	Consumers	Inhalation	Long-term systemic effects	66 mg/m3
	Consumers	Ingestion	Long-term systemic effects	8,6 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium metabisulphite	Fresh water	1 mg/l
	Marine water	0,1 mg/l
	Sewage treatment plant	75,4 mg/l

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Combined particulates and inorganic gas/vapour type (B-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : No data available



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

Colour : No data available
Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

No data available

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : Not applicable



Dihydrostreptomycin Sulfate Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 5918691-00010 Date of first issue: 20.05.2020

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

Hazardous decomposition products will be formed at elevated

temperatures.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

Thermal decomposition : Sulphur dioxide

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Components:

Dihydrostreptomycin sulphate:

Acute oral toxicity : LD50 (Rat): 9.000 - 25.000 mg/kg

LD50 Oral (Mouse): 30.000 mg/kg

Sodium metabisulphite:

Acute oral toxicity : LD50 (Rat): 1.540 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 5,5 mg/l

Exposure time: 4 h



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

Test atmosphere: dust/mist

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium metabisulphite:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Sodium metabisulphite:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium metabisulphite:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Test system: Human lymphocytes

Result: negative



Dihydrostreptomycin Sulfate Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 5918691-00010 Date of first issue: 20.05.2020

Sodium metabisulphite:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Subcutaneous Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 5 mg/kg body weight

Result : negative

Sodium metabisulphite:

Species : Mouse
Application Route : Ingestion
Exposure time : 24 Months
Result : negative

Remarks : Based on data from similar materials

Reproductive toxicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Effects on foetal develop: Test Type: Embryo-foetal development

ment

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 5 mg/kg body weight

Test Type: Embryo-foetal development

Species: Guinea pig

Application Route: Intramuscular

General Toxicity Maternal: LOAEL: 100 - 200 mg/kg body

weight

Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: Maternal toxicity observed., Embryotoxic effects and



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

adverse effects on the offspring were detected.

Sodium metabisulphite:

Effects on fertility : Test Type: Three-generation study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Dihydrostreptomycin sulphate:

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Dihydrostreptomycin sulphate:

Species : Guinea pig
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 90 d
Target Organs : ear

Symptoms : hearing loss

Species : Cat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 60 d
Target Organs : ear

Symptoms : ataxia, hearing loss, Reduced body weight

Species : Cat
LOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 21 d
Target Organs : ear

Symptoms : ataxia, hearing loss, Reduced body weight

Sodium metabisulphite:

Species : Rat



Dihydrostreptomycin Sulfate Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 5918691-00010 Date of first issue: 20.05.2020 2.1

NOAEL 110 mg/kg LOAEL 220 mg/kg Application Route Ingestion Exposure time 104 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dihydrostreptomycin sulphate:

General Information Symptoms: Erythema, hearing loss, Nausea, Rash, Vomiting,

Headache, hypotension

SECTION 12: Ecological information

12.1 Toxicity

Components:

Sodium metabisulphite:

LC50 (Oncorhynchus mykiss (rainbow trout)): 178 mg/l Toxicity to fish

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 89 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 43,8 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 33,3 mg/l

Exposure time: 72 h

EC10 (Pseudomonas putida): 30,8 mg/l Toxicity to microorganisms

Exposure time: 17 h

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 316 mg/l

Exposure time: 34 d

Species: Danio rerio (zebra fish) Method: OECD Test Guideline 210

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

NOEC: >= 10 mg/lExposure time: 21 d

Species: Daphnia magna (Water flea) ic toxicity)

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous goodIATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good



Dihydrostreptomycin Sulfate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.1
 30.09.2023
 5918691-00010
 Date of first issue: 20.05.2020

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.



Dihydrostreptomycin Sulfate Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 5918691-00010 Date of first issue: 20.05.2020 2.1 30.09.2023

Full text of H-Statements

H302 Harmful if swallowed.

H318 Causes serious eve damage.

Causes damage to organs through prolonged or repeated H372

exposure if swallowed.

Full text of other abbreviations

Acute Tox. Acute toxicity

Serious eye damage Eve Dam.

STOT RE Specific target organ toxicity - repeated exposure

2017/164/EU Europe. Commission Directive 2017/164/EU establishing a

fourth list of indicative occupational exposure limit values

ZA OEL South Africa. The Regulations for Hazardous Chemical

Agents, Occupational Exposure Limits

2017/164/EU / STEL Short term exposure limit 2017/164/EU / TWA Limit Value - eight hours

ZA OEL / OEL-RL Occupational Exposure Limit Restricted limit - 8- hour expo-

sure or equivalent (12 hour shifts)

ZA OEL / OEL- RL STEL/C Occupational Exposure Limit Restricted limit - Short term oc-

cupational exposure limits / ceiling limits

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information



Dihydrostreptomycin Sulfate Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.1 30.09.2023 5918691-00010 Date of first issue: 20.05.2020

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agentus http://cehn.com/process/

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Eye Irrit. 2 H319 Calculation method STOT RE 1 H372 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN

Sheet